Stephen C. Glover
Co-Founder, Chief Executive Officer, and President
Mr. Glover has over 32 years of business experience in biopharmaceuticals and life sciences. Mr. Glover is formally the Co-Founder of Coherus Biosciences where he was focused on the business strategy, partnerships, product development efforts and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins as well as Chief Business Officer of Insmed Incorporated. At Insmed, Mr. Glover was responsible for the creation of the biosimilar business unit and the divestiture of the business to Merck. As Chief Business Officer he led Insmed's strategic review process which resulted in the merger of Insmed and Transave. Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of the Andrx Labs which developed and marketed products in metabolic diseases and Men's Health, and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at Hoffman LaRoche, Amgen Inc. and IMS Health. Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. His transaction experience covers over 25 transactions totaling over $10 billion, and he serves on the Boards of PDS Biotechnology, INCON, and Asclepius Lifesciences.
Nicholas A. Labella, Jr. MS, RPh
Chief Scientific Officer, Senior VP Research and Development
Mr. LaBella is an experienced pharmaceutical executive with extensive expertise and core competency that spans over 34 years in Regulatory Affairs and Clinical Operations. His background includes hands-on experience in small molecule pharmaceutical development providing corporate leadership; strategic assessments; FDA interactions; preparation, submission and approval of NDA, ANDA and IND applications; and compliance with cGMP, cGCP, and cGLP. He has successfully designed, developed and executed pharmaceutical development programs in multiple therapeutic areas leading to NDA approvals. These therapeutic areas include cardiovascular, CNS, women’s health, anti-diabetic and anti-infective products. He managed a full spectrum of R&D departments; and served both on Executive Management Teams and as a Board of Director. Management experience includes growth and operations of a CRO organization with over 200 individuals. Mr. LaBella most recently served as Chief Scientific Officer at Insmed, Inc. (merged with Transave), VP of Development and Regulatory Affairs at Cardiokine, Inc, VP of Operations, Phase IV Division at Pharmanet (previously Medex Clinical Trail Services), VP of New Drug Development at Watson Laboratories (formally Circa Pharmaceuticals, where he was VP, Director of Research and Development, Director of Regulatory Affairs, and Director of Regulatory Investigational New Drugs). Mr. LaBella began his career at Sandoz Research Institute as a Senior Project Coordination Manager, followed by Associate Director of Regulatory Affairs at Lorex Pharmaceuticals. Mr. LaBella received his Bachelor of Science in Pharmacy from the University Of Connecticut School Of Pharmacy and his Master of Science in Drug Information and Communication from Arnold and Marie Schwartz College of Pharmacy, Long Island University. Mr. LaBella is a licensed Pharmacist and has published various publications and patents.
Pablo A. Guzman, MD, FACC
Chief Medical Officer
Dr. Guzman received his bachelor's degree in biology in 1971 from St Peter's College in Jersey City, his medical degree from the University of Puerto Rico School of Medicine in 1975 and his interventional cardiology fellowship at The Johns Hopkins Hospital in Baltimore in 1980 where then he joined the staff for the next 3 years. His duties included patient care, teaching, and both clinical and basic science research. Dr. Guzman became the Assistant Director of the cardiac catheterization lab, and Co-director of the permanent pacemaker lab at The Johns Hopkins Hospital, and also Co-director of the cardiac catheterization lab at Baltimore City Hospital. He has over 30 articles in peer reviewed journals and many abstracts, some of them presented in national meetings including the American Heart Association and the American College of Cardiology. While at Hopkins, Dr. Guzman became a Fellow of the American Heart Association Council on Clinical Cardiology, a member of the North American Society of Pacing and Electrophysiology, and a Fellow of The American College of Cardiology.
Dr. Guzman came to South Florida in 1983, and established a private practice in Cardiology. In 1987 he designed and became the Director of the Cardiac Catheterization Laboratory at Boca Raton Community Hospital (now Boca Regional Hospital) and a Fellow of the Society for Cardiac Angiography and Interventions. He then became the Associate Director of the Cardiac catheterization Laboratory at North Ridge Medical Center.
Dr. Guzman is a past president of the Caducean Society of Greater Fort Lauderdale, a past Chief of the Department of Cardiovascular and Pulmonary Diseases at North Ridge Medical Center, and a member of The North Ridge Medical Center Board. Dr. Guzman was a managing partner of Cardiology Associates of Fort Lauderdale, and is currently a member of The Broward County Medical Association. Dr. Guzman has been in the private practice of Medicine/ Cardiology in South Florida for 32 years.
Chief Commercial Officer
Ms. Cashmere has more than 25 years’ experience in business planning and execution for biopharmaceutical and medical device companies ranging in size from start-up to Fortune 100 companies. She formerly led the Marketing Communications function at Mako Surgical Corporation, an emerging robotic orthopedics company, where she was responsible for creating awareness and driving sales of $1+ Million Robotic Arm Systems and implants for partial knee and total hip arthroplasty. Substantial unit sales and revenue growth during her tenure culminated in a $1.65 Billion acquisition by Stryker. Ms. Cashmere also served as Sr. Vice President, New Product Marketing at Auxilium Pharmaceuticals, an emerging pharmaceutical company focused on men’s health and orphan indications. Responsibilities included creation of the New Product Marketing Business Unit, strategic opportunity assessment, pipeline prioritization, commercial oversight of clinical development, and masterminding new product commercialization strategies. Ms. Cashmere led Auxilium’s strategic partnership review process, resulting in out-licensing European rights of a key asset with multiple indications, Xiaflex, to Pfizer. Prior to Auxilium, Ms. Cashmere was Sr. Director, Marketing at Andrx Laboratories, responsible for a newly created business unit focusing on commercialization of pipeline products for men’s health. Earlier she held strategic marketing positions at Noven, Serono, and Abbott.
Senior Vice President, Finance and Administration
Mr. Wolfe has spent his career in various financial roles in the financial services, specialty finance and the pharmaceutical/healthcare industries. Most recently Mr. Wolfe has spent his time cultivating start-up organizations in various healthcare entities, often dealing with complicated business models to develop a financial framework for success for many of these first of their kind businesses. Mr. Wolfe has spent the last 17 years of his career in the healthcare industry with half of that time spent at Kos Pharmaceuticals, a publicly traded, fully-integrated specialty pharmaceutical company. Mr. Wolfe assisted in guiding Kos to 27 straight quarters of meeting or exceeding Wall Street quarterly earnings estimates. Finding the most cost-effective way to run a business through the design of more efficient systems is the hallmark of his career achievements. Mr. Wolfe has his BBA from the University of Miami and his MBA from the University of Pittsburgh.
Senior Vice President, Corporate Development
Ms. Uzbil brings more than 12 years of experience in academic technology commercialization, public-private partnerships, and early-stage fund-raising. Most recently, she founded a state-wide initiative, MTRAC, where she directed academic startup creation in partnership with industry, foundations, investors and 15 public universities in Michigan. Before the State of Michigan, Ms. Uzbil was the Duke principal working with the Blackstone Charitable Foundation and the Founding Director of the Duke-Coulter Translational Partnership. At Duke, she led commercialization, business development and fund raising activities for early stage therapeutics and devices leveraging a $5M commercialization grant into a $20M endowment for the Duke partnership. Ms. Uzbil’s industry experience includes Pfizer, managing CNS marketing research and evaluating new business opportunities, as well as her family’s business where she acquired new customers in Europe and initiated the first sale into the North American markets. Ms. Uzbil holds a Master of Engineering Management degree from Duke University with a concentration in Technology Management and Entrepreneurship and a BS in Chemical Engineering from Istanbul Technical University.
Douglas H. Farrar
Chief Technical Officer
Mr. Farrar has over 30 years of biotech industry experience. He spent 18 of those 30 years with Amgen, starting as a process development engineer in 1987 when the company had 250 employees. Prior to Amgen, he worked for Monsanto in their biotech animal health division, and after Amgen worked as senior vice president of operations for Insmed, and later as chief technical officer of Coherus. Throughout his career, Mr. Farrar has successfully worked with numerous corporate partners in the U.S., Europe and Japan. He has extensive experience in process development, clinical manufacturing and commercial manufacturing. His previous responsibilities include cell-line development, cell banking, fermentation/cell culture, purification, fill/finish, lyophilization, outsourced manufacturing, engineering and logistic operations. Mr. Farrar has been involved in filing 16 Investigational New Drug (IND) Applications and two Biological License Applications (BLAs). He has worked with dozens of products developed by recombinant DNA technology in microbial, yeast and mammalian cells manufactured in-house or at contract manufacturing facilities, and has built a process development pilot plant and multi-product clinical manufacturing plant from the ground up, as well as expanded, renovated and retooled commercial manufacturing facilities with hundreds of kilograms to multi-metric ton output capabilities. Mr. Farrar has hosted numerous US FDA, European and Health Canada prior approval and periodic inspections, and has been involved in many Pre-IND, EOP2, Pre-BLA, Post-Approval Change, Type C, and similar meetings with the FDA, MHRA, EMEA, and other regulatory agencies. He received a Bachelor of Science in chemical engineering from the University of Missouri, Rolla (now known as Missouri University of Science and Technology) in 1986.